|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
ATE12348T1
(de)
|
1980-11-10 |
1985-04-15 |
Gersonde Klaus Prof Dr |
Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
EP0088046B1
(de)
|
1982-02-17 |
1987-12-09 |
Ciba-Geigy Ag |
Lipide in wässriger Phase
|
|
DE3218121A1
(de)
|
1982-05-14 |
1983-11-17 |
Leskovar, Peter, Dr.-Ing., 8000 München |
Arzneimittel zur tumorbehandlung
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
DE3474511D1
(en)
|
1983-11-01 |
1988-11-17 |
Terumo Corp |
Pharmaceutical composition containing urokinase
|
|
JPS62126123A
(ja)
|
1985-11-28 |
1987-06-08 |
Shigeki Suzuki |
バルプロ酸の経皮吸収方法
|
|
EP0601058A4
(en)
|
1991-08-27 |
1995-05-31 |
Cygnus Therapeutic Systems |
TRANSDERMAL FORMULATIONS FOR PRRAZOSINE ADMINISTRATION.
|
|
CA2217014A1
(en)
|
1995-04-07 |
1996-10-10 |
Novartis Ag |
Iontophoretic transdermal system for the administration of at least two substances
|
|
US5736154A
(en)
|
1996-03-11 |
1998-04-07 |
Fuisz Technologies Ltd. |
Transdermal delivery system
|
|
FR2749514B1
(fr)
|
1996-06-11 |
1998-08-07 |
Hoechst Marion Roussel |
Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
|
|
US6479074B2
(en)
*
|
1996-10-24 |
2002-11-12 |
Pharmaceutical Applications Associates Llc |
Methods and transdermal compositions for pain relief
|
|
AU5495798A
(en)
*
|
1997-01-16 |
1998-08-07 |
Sekisui Chemical Co., Ltd. |
External preparations for percutaneous absorption
|
|
MXPA00012767A
(es)
|
1998-06-29 |
2002-08-09 |
Pharmaceuticals Applic Asociat |
Metodos y composiciones transdermicas para el alivio del dolor.
|
|
US6599912B1
(en)
|
1999-06-03 |
2003-07-29 |
Jessie L. -S. Au |
Methods and compositions for modulating cell proliferation and cell death
|
|
IL138686A0
(en)
|
1999-10-01 |
2001-10-31 |
Pfizer Prod Inc |
α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
|
|
AU2001277887B2
(en)
|
2000-07-14 |
2006-09-14 |
Transform Pharmaceuticals, Inc. |
System and method for optimizing tissue barrier transfer of compounds
|
|
US6682757B1
(en)
|
2000-11-16 |
2004-01-27 |
Euro-Celtique, S.A. |
Titratable dosage transdermal delivery system
|
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
|
EP1293205A1
(en)
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
|
|
MXPA04005361A
(es)
|
2001-12-13 |
2004-09-27 |
Vital Health Sciences Pyt Ltd |
Transporte transdermico de compuestos.
|
|
US6841565B1
(en)
*
|
2002-03-29 |
2005-01-11 |
The Ohio State University |
Treatment of patients with chronic lymphocytic leukemia
|
|
EP1638963B1
(en)
|
2003-05-20 |
2009-09-09 |
Novartis AG |
N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
|
|
EP1646628A1
(en)
|
2003-07-08 |
2006-04-19 |
Novartis AG |
Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
|
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
|
US8012944B2
(en)
*
|
2003-10-30 |
2011-09-06 |
Pharmascience Inc. |
Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
|
|
RU2413716C2
(ru)
|
2003-11-26 |
2011-03-10 |
Новартис Аг |
АМИДЫ δ-АМИНО-γ-ГИДРОКСИ-ω-АРИЛАЛКАНОВОЙ КИСЛОТЫ
|
|
WO2005065668A2
(en)
|
2003-12-29 |
2005-07-21 |
Qlt Usa, Inc. |
Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
|
|
WO2005105009A1
(en)
*
|
2004-04-26 |
2005-11-10 |
Cassel Douglas R |
Wound treatment patch for alleviating pain
|
|
KR100602434B1
(ko)
|
2004-09-10 |
2006-07-19 |
최상식 |
복수 개의 단위 구획을 포함하는 약물의 경피 투여용 패치
|
|
WO2007024574A2
(en)
|
2005-08-19 |
2007-03-01 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Topical formulations of histone deacetylase inhibitors and methods of using the same
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
WO2007041584A2
(en)
*
|
2005-10-03 |
2007-04-12 |
Combinatorx, Incorporated |
Implantable sensors, implantable pumps, and anti-scarring drug combinations
|
|
BRPI0520686A2
(pt)
|
2005-11-16 |
2009-05-19 |
Univ Mexico Nacional Autonoma |
uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer
|
|
ES2548240T3
(es)
|
2005-12-01 |
2015-10-15 |
Pronai Therapeutics, Inc. |
Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
|
|
US20110077215A1
(en)
|
2005-12-07 |
2011-03-31 |
The University Of Utah Research Foundation |
DNA Methylation As A Target For Diagnosis And Treatment Of Chronic Lymphocytic Leukema (CLL)
|
|
US8058258B2
(en)
|
2006-03-02 |
2011-11-15 |
Agency For Science, Technology And Research |
Methods for cancer therapy and stem cell modulation
|
|
US8585753B2
(en)
*
|
2006-03-04 |
2013-11-19 |
John James Scanlon |
Fibrillated biodegradable prosthesis
|
|
WO2007109178A2
(en)
|
2006-03-16 |
2007-09-27 |
Pharmacyclics, Inc. |
Indole derivatives as inhibitors of histone deacetylase
|
|
ES2444890T3
(es)
|
2006-03-31 |
2014-02-27 |
Erasmus University Medical Center Rotterdam |
Nueva composición para el control del crecimiento tumoral
|
|
AU2007247571A1
(en)
*
|
2006-05-05 |
2007-11-15 |
Coloplast A/S |
A pressure sensitive adhesive composition comprising cross-linked polyalkylene oxide and water absorbent hydrophilic agents
|
|
US20110104177A1
(en)
|
2006-12-28 |
2011-05-05 |
The Johns Hopkins University |
Histone deacetylase inhibitors, combination therapies and methods of use
|
|
EP2491923A3
(en)
|
2007-02-15 |
2012-12-26 |
Novartis AG |
Combinations of therapeutic agents for treating cancer
|
|
WO2008116163A1
(en)
|
2007-03-22 |
2008-09-25 |
Oregon Health & Science University |
Therapeutic drug combinations for treatment of b-cell malignancies
|
|
US8163279B2
(en)
|
2007-04-13 |
2012-04-24 |
Stemline Therapeutics, Inc. |
IL3Rα antibody conjugates and uses thereof
|
|
US20090025274A1
(en)
|
2007-07-23 |
2009-01-29 |
Tim Lail |
Animal trap
|
|
JP2011500086A
(ja)
|
2007-10-22 |
2011-01-06 |
シェーリング コーポレイション |
完全ヒト抗ｖｅｇｆ抗体および使用方法
|
|
WO2009067453A1
(en)
*
|
2007-11-19 |
2009-05-28 |
Syndax Pharmaceuticals, Inc. |
Combinations of hdac inhibitors and proteasome inhibitors
|
|
US20110053991A1
(en)
*
|
2007-11-19 |
2011-03-03 |
Gore Lia |
Treatment of Histone Deacetylase Mediated Disorders
|
|
PT2695609T
(pt)
|
2008-05-15 |
2020-03-02 |
Celgene Corp |
Formulações orais de análogos da citidina e métodos de utilização dos mesmos
|
|
WO2009155477A1
(en)
|
2008-06-19 |
2009-12-23 |
The Trustees Of The University Of Pennsylvania |
Inducible regulatory t-cell generation for hematopoietic transplants
|
|
WO2010020787A1
(en)
|
2008-08-22 |
2010-02-25 |
Oncomethylome Sciences Sa |
Diagnosis and treatment of tumours
|
|
US9028833B2
(en)
*
|
2012-12-13 |
2015-05-12 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US20100298255A1
(en)
*
|
2009-05-19 |
2010-11-25 |
Vivia Biotech S.L. |
Methods for providing personalized medicine test ex vivo for hematological neoplasms
|
|
US8491927B2
(en)
*
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
|
JP5548470B2
(ja)
*
|
2010-02-16 |
2014-07-16 |
日本碍子株式会社 |
ハニカム触媒体
|
|
US20110245154A1
(en)
*
|
2010-03-11 |
2011-10-06 |
Hemaquest Pharmaceuticals, Inc. |
Methods and Compositions for Treating Viral or Virally-Induced Conditions
|
|
EP2382993A1
(en)
*
|
2010-04-19 |
2011-11-02 |
KTB Tumorforschungsgesellschaft mbH |
Combination of drugs with protein-binding prodrugs
|
|
WO2012044936A1
(en)
*
|
2010-09-30 |
2012-04-05 |
Portola Pharmaceuticals, Inc. |
Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
|
|
SI2786756T1
(sl)
*
|
2010-11-12 |
2020-07-31 |
Pharma Mar S.A. |
Kombinirana terapija z zaviralci topizomeraze
|
|
US20130004481A1
(en)
*
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
TW201300385A
(zh)
*
|
2011-04-08 |
2013-01-01 |
Afraxis Inc |
用於治療ｃｎｓ病症和癌症的８－乙基－６－（芳基）吡啶并［２，３－ｄ］嘧啶－７（８ｈ）－酮
|
|
WO2012142480A1
(en)
*
|
2011-04-14 |
2012-10-18 |
Beth Israel Deaconess Medical Center, Inc. |
Chimeric rna oligonucleotides and uses thereof
|
|
US20140170148A1
(en)
*
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2
|
|
US9896730B2
(en)
*
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
MX2014000130A
(es)
*
|
2011-06-28 |
2014-05-01 |
Pharmacyclics Inc |
Procedimientos y composiciones para la inhibicion de resorcion osea.
|
|
BR112014010417A2
(pt)
*
|
2011-11-01 |
2014-11-18 |
Celgene Corp |
Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
|
|
AU2012330498A1
(en)
*
|
2011-12-09 |
2013-06-27 |
Afraxis Holdings, Inc. |
PAK inhibitors for the treatment of cancer
|
|
EP2854811A1
(en)
*
|
2012-05-31 |
2015-04-08 |
Amgen Inc. |
Use of amg 900 for the treatment of cancer
|
|
KR20150015021A
(ko)
*
|
2012-06-04 |
2015-02-09 |
파마시클릭스, 인코포레이티드 |
브루톤 타이로신 키나아제 저해제의 결정 형태
|
|
WO2014009319A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
Indolinone derivatives anticancer compounds
|
|
WO2014009318A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
|
|
PE20150617A1
(es)
*
|
2012-08-09 |
2015-05-21 |
Celgene Corp |
Formas solidas de 3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona o un estereoisomero del mismo, de sus sales, y composiciones que comprenden las mismas
|
|
PL2882442T3
(pl)
*
|
2012-08-09 |
2021-12-13 |
Celgene Corporation |
Sposoby leczenia nowotworów z wykorzystaniem 3-(4-((4-(morfolinometylo)benzylo)oksy)-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu
|
|
US9682143B2
(en)
*
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9315567B2
(en)
*
|
2012-08-14 |
2016-04-19 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US20140120083A1
(en)
*
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|